Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 October 2024 | Story Anthony Mthembu | Photo Supplied
Prof Tameshnie Deane
Prof Tameshnie Deane, Vice-Dean: Research, Postgraduate Studies and Internationalisation in the Faculty of Law at the University of the Free State (UFS).

The Faculty of Law at the University of the Free State (UFS) has appointed Prof Tameshnie Deane as Vice-Dean: Research, Postgraduate Studies and Internationalisation. Prof Deane officially assumed this role on 1 July 2024, following over two decades as a Professor and Head of the Criminal Law Unit at the University of South Africa (UNISA).

Prof Deane, who has approached this new position with great enthusiasm, describes it as a significant opportunity. ‘’This role allows me to influence the future of academic research and postgraduate education at UFS,’’ she said.

Support for postgraduate students

Prof Deane elaborated on her vision, saying, “My aim is to develop and implement strategies that elevate the quality and impact of research, foster innovation, and support postgraduate students in achieving their academic and professional goals.”

Among her top priorities is strengthening support for postgraduate students at the UFS. “I plan to introduce comprehensive mentorship programmes where experienced faculty members guide students through their academic and research journeys. We will offer training in key skills such as legal writing, research methodologies, and public speaking, while also prioritising initiatives to support their mental and emotional well-being,’’ she explained.

Prof Deane emphasised that creating a dynamic and supportive environment will contribute to academic excellence and personal growth for postgraduate students at the UFS.

Enhancing internationalisation and strategic collaborations

Prof Deane is also committed to advancing the internationalisation of the Faculty of Law.  “We aim to provide opportunities for international collaboration and exchange, which will broaden the scope and impact of our research and postgraduate programmes,’’ she said.

Improving research quality and output remains a core objective, with Prof Deane identifying this as central to her new role.

One of the initiatives Prof Deane is eager to lead is the development of strategic partnerships with industry and academic institutions. “Collaborations like these will provide invaluable resources for research projects,” she noted.

To foster these partnerships, Prof Deane plans to leverage technology to strengthen communication and collaboration, support relationship-building events, and promote interdisciplinary projects that encourage diverse perspectives and innovative solutions. 

News Archive

National Department of Health invests R53.5 million in UFS laboratory
2016-02-04

Description: Dr Derek Litthauer Tags: Dr Derek Litthauer

Dr Derek Litthauer
Photo: Supplied

This year has started off on a high note for Dr Derek Litthauer and his team at the South African National Control Laboratory (NCL) for Biological Products. The National Department of Health has awarded the NCL a contract to the value of R53.5 million to continue testing vaccines for the next three years.

Vaccines are biological medicines used to ensure healthy populations by preventing many diseases. The World Health Organization (WHO) estimates that, worldwide, about 5.2 million children under six years old die annually. Of these deaths, 29% are vaccine preventable. Research has revealed that vaccines prevent about 6 million deaths each year globally. Safe and effective vaccines are essential public health tools, which are strictly regulated internationally. It is the NCL’s responsibility to perform quality control testing on all vaccines to be used on humans in South Africa.

This laboratory, the only one of its kind in Africa, receives samples of vaccines from manufacturers and importers for rigorous evaluation and testing. No vaccine may be used in South Africa without a release certificate issued by the Control Lab, certifying that the vaccine is suitable for human use.

The contract is a commitment to ensuring that only vaccines of the highest quality are used in South Africa.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept